Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Celecoxib for Chronic Uveitis
NCT02131012Phase 1Terminated
- Sponsor
- Vanderbilt University
- Start
- Jun 2015
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of celecoxib in uveitis and macular edema, sponsored by Vanderbilt University. Primary endpoint: Safety at 12 weeks. Started Jun 2015; status: terminated.
02
Drugs
celecoxib
03
Conditions
uveitismacular edema
Beyond the preview
Go deeper on NCT02131012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131012.